Resultados de procura - Anu Nigam
- Mostrando 1 - 3 Resultados de 3
-
1
A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmac... por Andrew L. Frelinger, Ronald Lee, Darcy J. Mulford, Jingtao Wu, Sai Nudurupati, Anu Nigam, Julie K. Brooks, Deepak L. Bhatt, Alan D. Michelson
Publicado 2012Artigo -
2
Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (In... por Andrew L. Frelinger, Deepak L. Bhatt, Ronald Lee, Darcy J. Mulford, Jingtao Wu, Sai Nudurupati, Anu Nigam, Michael Lampa, Julie K. Brooks, Marc R. Barnard, Alan D. Michelson
Publicado 2013Artigo -
3
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction por Jemy A. Gutierrez, Wei Liu, Sylvie Perez, Gang Xing, Gabriele E. Sonnenberg, Kou Kou, Matt Blatnik, Richard Allen, Yan Weng, Nicholas B. Vera, Kristin Chidsey, Arthur Bergman, Veena Somayaji, Collin Crowley, Michelle Clasquin, Anu Nigam, Melissa A. Fulham, Derek M. Erion, Trenton T. Ross, William P. Esler, Thomas V. Magee, Jeffrey A. Pfefferkorn, Kendra K. Bence, Morris J. Birnbaum, Gregory J. Tesz
Publicado 2021Artigo
Ferramentas de procura:
Materias Relacionadas
Internal medicine
Medicine
Aspirin
CYP2C19
Clopidogrel
Cytochrome P450
Metabolism
P2Y12
Pharmacodynamics
Pharmacokinetics
Pharmacology
Alternative medicine
Biochemistry
Biology
Cholesterol
Crossover study
Diabetes mellitus
Disease
Endocrinology
Esomeprazole
Fatty liver
Fructose
Hyperinsulinemia
Hypertriglyceridemia
Insulin resistance
Lansoprazole
Lipid metabolism
Lipogenesis
Metabolic syndrome
Omeprazole